Afternoon Session
Elisabeth Björk (AstraZeneca)
Welcome
John Buse (USA), Angelo Avogaro (Italy)
SGLT2 inhibitors, GLP-1 receptor agonists, and metabolism: What’s new in 2020?
Hiddo Lambers Heerspink (Netherlands)
Closing in on mechanisms of renoprotection
Javed Butler (USA)
Understanding the mechanistics and outstanding challenges in heart failure
Jiten Vora (UK)
Panel discussion
Jiten Vora (UK), Regina Fritsche-Danielson (AstraZeneca)
Closing remarks